We describe collection and purification of peripheral blood CD34
Summary:
We describe collection and purification of peripheral blood CD34
؉ cells from volunteer, normal donors and allogeneic stem cell donors. A total of 98 aphereses were performed on 68 volunteer donors using peripheral venous access. The mean number of nucleated cells collected was 4. 6 The collection of large numbers of peripheral blood progenitor cells (PBPCs) mobilized after chemotherapy or with recombinant cytokines has become an accepted method to obtain cells for autologous stem cell support during intensive chemotherapy as well as for autologous transplantation after myeloablative therapy. [1] [2] [3] [4] [5] [6] [7] [8] Additionally, cytokine-mob-ilized PBPCs are now being used in related and unrelated allogeneic transplantation. Apheresis collection is well tolerated and is potentially less invasive than bone marrow harvest. Recently, attention has focused on the number of CD34 + cells in the PBPCs as the component responsible for the time to recovery after intensive chemotherapy and the cells likely responsible for long-term engraftment and reconstitution of hematopoiesis. [9] [10] [11] [12] [13] [14] [15] Therefore, an enriched population of CD34 + cells may be a superior donor product. In addition, isolation of CD34 + cells may decrease contaminating tumor cells, 16, 17 deplete mature T cells for modulation of graft-versus-host disease [18] [19] [20] and provide the target of choice for both ex vivo expansion 21, 22 and gene transfer. [23] [24] [25] [26] Antibodies directed against the CD34 antigen have provided a means for rapidly purifying and concentrating CD34
+ cells using immunomagnetic techniques. 27, 28 Although apheresis devices have been shown to be effective for collecting large numbers of nucleated white blood cells, the number of CD34 + cells collected is highly variable depending on factors such as the individual's response to cytokine and the number of blood volumes processed. 29, 30 Reliable predictors of CD34 + cell purity, recovery, and clonogenic potential are currently needed and would be advantageous in planning efficient use of growth factor during mobilization and minimizing procedural discomfort to the donor.
Although there is a large experience with apheresis from patients on cytotoxic therapeutic regimens, limited data are available from normal volunteers on the safety, efficacy and ability to collect purified CD34 + cells. We present the results of a large series of aphereses (n = 98) and CD34 + cell isolations using the Isolex 300i magnetic separator (n = 30) on G-CSF-mobilized PBPCs from normal volunteers. Adverse events, absolute numbers of cells collected, and CD34
+ cell purification are presented. In addition, we present results from 38 CD34
+ cell isolations using the Isolex 300i performed on normal allogeneic stem cell donors. These data provide further evidence for the safety and feasibility of collecting adequate numbers of CD34 + cells from the peripheral blood of normal donors for stem cell support, transplantation and gene therapy.
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Materials and methods
PBPC mobilization and collection
Mobilized PBPC collections were performed on both normal, healthy volunteer donors for research use and on normal allogeneic stem cell donors for stem cell transplants in separate research studies. These studies were approved by the Indiana University-Purdue University Indianapolis Institutional Review Board and participants provided written informed consent. A history and physical examination were performed prior to starting G-CSF and on the day of donation.
Mobilized PBPCs from the volunteer donors were collected on the COBE Spectra (Cobe-BCT, Lakewood, CO, USA) approximately 24 h after completing four daily doses of 480 g of G-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA). Venous access was obtained with a 16-gauge intravenous catheter in the antecubital fossa with return through an 18-gauge catheter in the opposite arm. Approximately two blood volumes were processed per collection that lasted approximately 3 h. ACD-A was the only anticoagulant used. Adverse reactions during mobilization and apheresis were scored on a scale of 1-4, from low to high severity. Symptoms related to hypocalcemia were treated with oral calcium (Tums, SmithKline Beecham, Pittsburgh, PA, USA). CD34
+ cells were purified from 29 of the apheresis collections. One additional apheresis product used for isolation of CD34 + cells was obtained from the University of Minnesota from a volunteer, normal donor collected on a protocol approved by the local Institutional Review Board. Information from this apheresis product is included only with the CD34 + purification data set and not the collection data set.
Mobilized PBPCs were collected from the allogeneic stem cell donors after 3-4 days of G-CSF administration. Collections continued with daily G-CSF administration at 10-20 g/kg until 7.5 × 10 6 CD34 + cells/kg (or 3 × 10 6 CD34 + cells/kg for one donor) were collected or for a maximum of 4 days of apheresis. Four of the 18 allogeneic stem cell donors required a percutaneous central venous catheter.
CD34
+ progenitor cell isolation
Mobilized peripheral blood progenitor cells were transferred to a 600-ml apheresis collection bag and 0. 
Immunophenotyping
All antibodies were purchased from Becton Dickinson and used at concentrations recommended by the manufacturer (San Jose, CA, USA). Initial characterization of cells expressing CD34 in the collected product was performed on a FITC CD45 white blood cell gate using the HPCA-2 anti-CD34 antibody. Additional immunophenotyping was performed on products selected on the Isolex 300i. Approximately 500 000 unselected cells or 100 000 selected cells from the CD34 column were stained with 10 l of directly conjugated monoclonal antibody for 20 min at 4°C. Cells were washed once with RBC Lysis buffer (Becton Dickinson, Mountain View, CA, USA), then with PBS containing 1% human serum albumin and 0.1% sodium azide.
All centrifugations were at 1800 r.p.m. for 5 min at room temperature. Cells were either analyzed immediately or fixed with 1% para-formaldehyde and stored at 4°C until analysis could be performed. + cells in the total number of nucleated cells. The relative percentage of CD34 + cells was determined using the mean of three separate measurements based on CD34 FITC/HLA-DR PE, CD34 FITC/CD38 PE and HLA-DR FITC/CD34 PE antibody combinations. Briefly, an analysis gate was drawn around the entire MNC population of events greater than 95% CD45 + /CD14 + compared to a mouse isotype-specific control. The level of fluorescence of CD34-FITC and CD34-PE-conjugated events was recorded by quadrant statistics calculated by CellQuest software. Data were reported as the mean relative percentage of CD34
+ events (n = 3) detected within the pre-and post-column products. The number of nucleated cells within the starting product multiplied by the percentage of CD34 + events equals the expected or theoretical yield. The purity of the selected product is expressed as the percentage of CD34 + events measured in the final selected product. The actual CD34 + yield is determined by the purity multiplied by the total number of nucleated cells in the selected product. Recovery is the ratio of the actual yield to the theoretical yield of CD34
+ cells.
Statistical analysis
Analyses of G-CSF dose, donor weight, mobilized nucleated cells and the percentage and total CD34 + cell counts from the normal donors were performed using twosided t-tests. Because some donors had multiple aphereses, weighted means were used for the statistical test, with weights corresponding to the inverse of the variance of the multiple observations. Correlations (r 2 values) between study parameters were determined using the curve fitting function on graphical analyses generated in Cricket Graph version 1.3.1 (Cricket Software, Malvern, PA, USA) and analyzed using the t-test. All tests were conducted at 0.05 level of significance.
Results
PBPC donors
There were 26 male and 42 female adult, healthy volunteer donors with an average age of 30 Ϯ 6 years (range who underwent a total of 98 separate mobilizations and apheresis collections. PBPCs were mobilized with 480 g/day of G-CSF administered subcutaneously for 4 days. The average donor weight was 77.7 Ϯ 19 kg (range 51-136 kg) resulting in G-CSF doses of 3.5-9.4 g/kg/day. Each apheresis consisted of a two blood volume collection. CD34
+ cell data were available on 77 collections. In addition, 18 normal allogeneic stem cell donors were mobilized with G-CSF doses of 10-20 g/kg/day for 4-7 days. There were 12 male donors and six female donors with an average age of 42 Ϯ 10 years and average donor weight of 83.3 Ϯ 20.3 kg (range 52-145 kg). Nine donors underwent 1 day of apheresis, six underwent 2 days and three underwent 3 days. Eight of the apheresis products were split in two for separate CD34
+ isolation procedures to accommodate the maximal number of nucleated cells that could be utilized during a single procedure. CD34 + cells were isolated from the 38 apheresis samples. The data were analyzed separately from the volunteer donors.
Adverse events
G-CSF PBPC mobilization and apheresis were well tolerated by the volunteer, normal donors during the 98 collections. Table 1 indicates the number of adverse events. No donor had complaints which were scored greater than 1 on a scale of 1-4. During most collections (78%), donors Number of collections where subjects experienced adverse events during G-CSF mobilization of PBPCs and apheresis. All symptoms were mild, classified as level 1 on a scale of 1 to 4.
Bone Marrow Transplantation described mild bone pain during G-CSF administration. Mild myalgias and mild headaches were present in donors during 8% and 10% of the collections, respectively. These symptoms were treated symptomatically with acetaminophen in 85 of the collections. There were no major differences in adverse events based upon the dose/kg of G-CSF (data not shown). In contrast, five of 18 of the normal allogeneic stem cell donors required oral narcotics for complaints of pain attributed to G-CSF administration.
Mild tingling of the lips or extremities were present in donors during approximately 40% of the aphereses and responded promptly to treatment with oral calcium. At the completion of apheresis there was a decrease in the platelet count ( Table 2) . No patient developed thrombocytopenia below 90 × 10 9 /l. Two aphereses were terminated early, one due to a vasovagal syncopal reaction during intravenous access placement and another to loss of intravenous access, and neither had sufficient product to be included in the collection data. Similarly, 11 of 18 of the normal allogeneic stem cell donors experienced numbness or tingling and two of 18 experienced nausea during the apheresis procedure. The lowest platelet count after one day of apheresis was 73 × 10 9 /l, however, two of the stem cell donors had platelet counts of 20-35 × 10 9 /l after 2-3 days of apheresis.
Peripheral blood stem mobilization and apheresis
Mobilization of PBPC from the volunteer, normal donors with G-CSF for 4 days resulted in a 5-to 10-fold increase in the peripheral WBC (Table 2 ). In no case did the WBC exceed 70 × 10 9 /l. The mean WBC in female subjects after 4 days of G-CSF mobilization was higher than in male subjects, 40.1 Ϯ 10 × 10 9 /l vs 30.1 Ϯ 9 × 10 9 /l (P Ͻ 0.001) possibly due to a higher mean dose of G-CSF/kg, 6.7 Ϯ 1.2 g/kg vs 4.8 Ϯ 1.1 g/kg (P Ͻ 0.001), respectively. The mean percentage of CD34 + cells in the collection, however, was significantly higher in male subjects than in female subjects, 0.7 Ϯ 0.01% vs 0.32 Ϯ 0.01% (P Ͻ 0.001), respectively.
The mean number of nucleated cells collected with the single apheresis was 4.6 Ϯ 1.5 × 10 10 cells (Table 3) . A mean of 1.9 Ϯ 1.7 × 10 8 CD34 + cells was collected which corresponded to 2.7 Ϯ 2.2 × 10 6 CD34 + cells/kg ( Table 3 ). The mean yield was 27 Ϯ 18 × , and the number of CD34
+ cells/kg collected, 2.4 Ϯ 1.7 and 2.9 Ϯ 2.4, was not statistically significant, P = 0.32 and P = 0.22, respectively (Table 3) . Only three donors mobilized less than 0.9 × Mean peripheral blood counts × 10 9 /l at baseline, pre-apheresis after 4 days of G-CSF mobilization and after apheresis (Ϯ s.d.). = 0.57, P Ͻ 0.001). Nineteen volunteer donors had more than one collection with a mean of 6 Ϯ 4 months between collections (range 1-15 months). Thirteen underwent two, three underwent three, two underwent four and and one underwent six collections. The variation between collections was evaluated by comparing the difference in intrapersonal standard deviation from zero, the value for no intrapersonal variation. The mean standard deviations for WBC after G-CSF administration, the total number of nucleated cells collected and the total number of CD34 + cells collected from individual donors with multiple collections differed significantly from zero, P Ͻ 0.001, P = 0.001, and P = 0.015, respectively. This suggested a relatively large amount of intrapersonal variation between collections. There was no significant difference between the total number of CD34 + cells collected between subjects who underwent one (2.86 Ϯ 1.76 × 10 6 ) or more than one (2.18 Ϯ 1.2 × 10 6 ) collection (P = 0.19). However, the relative number of CD34 + cells collected from subjects who had a collection less than 3 months after the first apheresis (n = 5, 69 Ϯ 10%) was significantly lower (P = 0.045) compared to subjects who had collections greater than 3 months apart (n = 8, 183 Ϯ 195%).
Mobilization of PBPC from the allogeneic stem cell transplant donors yielded a mean of 12.1 Ϯ 4.8 × 10 (Figure 1a) .
The purity of the product isolated by the Isolex 300i cor- Mean total nucleated cells and CD34 + cells in the initial apheresis product prior to selection on the Isolex 300i column and in the final product after the selection process (Ϯ s.d.). 
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Discussion
The use of mobilized PBPCs has for the most part replaced bone marrow as the product of choice for autologous stem cell support during myelosuppressive and myeloablative chemotherapy. It is increasingly used for pediatric and adult donors in the allogeneic transplantation setting. 1, 31 Mobilized PBPCs appear to be the product of choice for isolating target CD34
+ cells for genetic manipulation of hematopoietic stem cells. Mobilized PBPC are capable of reconstituting hematopoiesis after myeloablative therapies. CD34 + cells normally constitute 1-3% of bone marrow mononuclear cells and 0.01-0.05% of unmobilized peripheral blood mononuclear cells. Stimulation with G-CSF can increase the peripheral blood CD34 + content to 0.5-1%. The optimal methods for peripheral blood mobilization, however, remain unclear. G-CSF has been the most widely reported stimulus for mobilizing PBPC. However, doses have ranged from 5 to 32 g/kg/day for 3-7 days in normal donors and patients recovering from myelosuppressive therapy. Our approach in adult volunteer, normal donors has been to use G-CSF at 480 g/day for 4 days followed by apheresis approximately 24 h after the last dose. This approach has allowed us to successfully collect a mean of 1.9 ϫ 10 8 CD34 + cells or 2.7 ϫ 10 6 CD34 + cells/kg with a single two blood volume apheresis. Donor weight and the total number of nucleated cells collected influenced the total number CD34 + cells collected. Differences in gender and peripheral WBC and mononuclear count after mobilization were not significant factors in the number of CD34 + cells collected.
Although there is substantial information on the results of isolating CD34
+ cells from patients with malignancies, there are limited data on normal donors and most reports represent small numbers of procedures at any one institution. 27, 29, [32] [33] [34] [35] [36] Our results of 30 CD34 + cell isolations from volunteer donors and 38 CD34
+ cell isolations from allogeneic stem cell donors using the Isolex 300i system indicate that CD34
+ purification from normal donors is similar to the results obtained in patients with malignancy mobilized with G-CSF and/or cytotoxic therapeutic agents. 18, 21, 22, 27, 29, [32] [33] [34] We recovered approximately 45% of the CD34 + cells from the apheresis product and the purified product was comprised of approximately 85% CD34 + cells, representing a two log purification. There was a corresponding decrease in B cells, T cells and NK cells by approximately two to three logs.
The results from the volunteer donors and the allogeneic stem cell donors were remarkably similar. The strongest determinant of the absolute number of CD34 + cells isolated with the Isolex 300i was the total number of CD34 + cells placed on the column. The percentage of CD34 + cells recovered, however, was independent of the number of CD34 + placed on the column, indicating that efficient isolation of CD34 + cells occurred over a wide range of CD34 + cell input. There was no relationship between the absolute numbers of CD34
+ cells isolated and number of nucleated cells placed on the column. The percentage of CD34 + cells recovered was decreased with increasing numbers of nucleated cells placed on the column with samples from the volunteer donors but not the allogeneic stem cell donors. When the data sets were combined, however, there was no correlation between the percentage of CD34
+ cells recovered and the number of nucleated cells placed on the column (n = 68, r 2 = 0.039, P = 0.11). The purity of the final product correlated with the number of CD34 + cells placed on the device and was not influenced by the total number of nucleated cells used for selection or the percentage of CD34 + cells recovered. These observations support efforts to improve CD34 + mobilization with agents such as stem cell factor 61, 62 and flt3 ligand. 63 Our experience provides further evidence that G-CSF mobilization and apheresis are safe for normal adult donors. Most of the donors experienced minor toxicities including bone pain during G-CSF mobilization and/or tingling during the apheresis procedure. The symptoms were mild in all cases and responded to acetaminophen and oral calcium, respectively. The procedure itself was well tolerated using only peripheral venous access.
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